PMID: 6539565Jun 1, 1984Paper

Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study

American Journal of Clinical Oncology
J T ThigpenH D Homesley

Abstract

Twenty-five patients with advanced or recurrent endometrial carcinoma no longer amenable to control with surgery, radiotherapy, hormonal therapy, or higher-priority chemotherapy were treated with cisplatin 50 mg/m2 intravenously every 3 weeks. Only one objective response, a partial response, was observed among the 25 patients (4%). Twenty patients (80%) exhibited stable disease for more than 1 month, while four patients (16%) progressed less than 1 month after initiating chemotherapy. Adverse effects included leukopenia (28%), thrombocytopenia (40%), nausea and vomiting (74%), and azotemia (37%). Only one patient experienced life-threatening toxicity. Cisplatin thus appears tolerable but only minimally active when given at the dose and schedule tested to patients with endometrial carcinoma who have previously demonstrated progression of disease on chemotherapy with known activity.

Citations

Nov 30, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yasukazu SagawaKeiichi Isaka
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H KunitohT Taguchi
Mar 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R K GregoryM E Gore
Dec 13, 2002·American Journal of Clinical Oncology·Robert F AsburyUNKNOWN Gynecologic Oncology Group
Mar 25, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Warner K HuhDavid E Cohn
Oct 27, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Alessia Di LeggeDomenica Lorusso
May 29, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Rachel Nicole GrishamJason Konner
Apr 20, 2013·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Vicky MakkerCarol A Aghajanian
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Don S DizonRonald D Alvarez
Jan 1, 1990·Seminars in Surgical Oncology·L S Morgan
Feb 25, 2014·Seminars in Oncology Nursing·Heidi S DonovanLari Wenzel
Dec 1, 1987·American Journal of Obstetrics and Gynecology·D E PittawayJ W Douglas
Apr 15, 2008·Critical Reviews in Oncology/hematology·Jalid SehouliAlexander Mustea
Feb 27, 2008·Gynecologic Oncology·D PectasidesT Economopoulos
Jan 2, 2007·Cancer Treatment Reviews·D PectasidesT Economopoulos
Jan 1, 1989·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·A RamahiG Deppe
Mar 18, 1999·Hematology/oncology Clinics of North America·M A Quinn
Mar 8, 2016·Expert Opinion on Investigational Drugs·Claudia MarchettiPierluigi Benedetti Panici
Jul 31, 2001·Best Practice & Research. Clinical Obstetrics & Gynaecology·C Steer, P Harper
Feb 10, 2004·Gynecologic Oncology·Katherine Y LookUNKNOWN Gynecologic Oncology Group (GOG) Study
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Holly H GallionUNKNOWN Gynecologic Oncology Group Study
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Tate ThigpenShu Liao
Oct 15, 1987·Cancer·T ThigpenR McGehee
May 2, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F H van WijkHelena C van Doorn
May 2, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·F H van WijkH C van Doorn
Feb 3, 2006·Gynäkologisch-geburtshilfliche Rundschau·Mathias K Fehr, Matthias S Streich
Jul 11, 2009·Expert Review of Anticancer Therapy·Thanh H Dellinger, Bradley J Monk
Dec 25, 2012·Expert Review of Anticancer Therapy·Diana P EnglishAlessandro D Santin
Jul 28, 2010·The Oncologist·J Alejandro Rauh-Hain, Marcela G Del Carmen
Jun 10, 2016·Journal of the Royal Society, Interface·Elif TekinPamela J Yeh
Apr 20, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S B Decruze, J A Green
Jun 22, 2021·Gynecologic Oncology·David A BarringtonKristin L Bixel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.